{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T12:43:03Z","timestamp":1784119383651,"version":"3.55.0"},"reference-count":128,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2018,4,19]],"date-time":"2018-04-19T00:00:00Z","timestamp":1524096000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2018,6]]},"abstract":"<jats:title>Summary<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>There is a great unmet clinical need for efficacious, tolerable, economical and orally administrated drugs for the treatment of inflammatory bowel disease (<jats:styled-content style=\"fixed-case\">IBD<\/jats:styled-content>). New therapeutic avenues have become possible including the development of medications that target specific genetic pathways found to be relevant in other immune mediated diseases.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aims<\/jats:title><jats:p>To provide an overview of recent clinical trials for new generation oral targeted medications that may have a future role in <jats:styled-content style=\"fixed-case\">IBD<\/jats:styled-content> management.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Pubmed and Medline searches were performed up to 1 March 2018 using keywords: \u201c<jats:styled-content style=\"fixed-case\">IBD<\/jats:styled-content>\u201d, \u201c<jats:styled-content style=\"fixed-case\">UC<\/jats:styled-content>\u201d, \u201c<jats:styled-content style=\"fixed-case\">CD<\/jats:styled-content>\u201d, \u201cinflammatory bowel disease\u201d \u201culcerative colitis\u201d, \u201cCrohn's disease\u201d in combination with \u201cphase\u201d, \u201cstudy\u201d, \u201ctrial\u201d and \u201coral\u201d. A manual search of the clinical trial register, article reference lists, abstracts from meetings of <jats:italic>Digestive Disease Week, United European Gastroenterology Week<\/jats:italic> and <jats:italic><jats:styled-content style=\"fixed-case\">ECCO<\/jats:styled-content> congress<\/jats:italic> were also conducted.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In randomised controlled trials primary efficacy endpoints were met for tofacitinib (<jats:styled-content style=\"fixed-case\">JAK<\/jats:styled-content> 1\/3 inhibitor\u2010phase <jats:styled-content style=\"fixed-case\">III<\/jats:styled-content>), upadacitinib (<jats:styled-content style=\"fixed-case\">JAK<\/jats:styled-content> 1 inhibitor\u2010phase <jats:styled-content style=\"fixed-case\">II<\/jats:styled-content>) and AJM300 (\u03b14\u2010integrin antagonist\u2010phase <jats:styled-content style=\"fixed-case\">II<\/jats:styled-content>) in ulcerative colitis. Ozanimod (S1P receptor agonist\u2010phase <jats:styled-content style=\"fixed-case\">II<\/jats:styled-content>) also demonstrated clinical remission. For Crohn's disease, filgotinib (<jats:styled-content style=\"fixed-case\">JAK<\/jats:styled-content>1 inhibitor\u2010phase <jats:styled-content style=\"fixed-case\">II<\/jats:styled-content>) met primary endpoints and laquinimod (quinolone\u20103\u2010carboxide small molecule\u2010phase <jats:styled-content style=\"fixed-case\">II<\/jats:styled-content>) was also efficacious. Trials using mongersen (<jats:styled-content style=\"fixed-case\">SMAD<\/jats:styled-content>7 inhibitor) and vidofludimus (dihydroorotate dehydrogenase inhibitor) have been halted.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This is potentially the start of an exciting new era in which multiple therapeutic options are at the disposal of physicians to treat <jats:styled-content style=\"fixed-case\">IBD<\/jats:styled-content> on an individualised basis. Head\u2010to\u2010head studies with existing treatments and longer term safety data are needed for this to be possible.<\/jats:p><\/jats:sec>","DOI":"10.1111\/apt.14669","type":"journal-article","created":{"date-parts":[[2018,4,19]],"date-time":"2018-04-19T17:08:15Z","timestamp":1524157695000},"page":"1610-1622","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Review article: novel oral\u2010targeted therapies in inflammatory bowel disease"],"prefix":"10.1111","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6264-4560","authenticated-orcid":false,"given":"J. R.","family":"White","sequence":"first","affiliation":[{"name":"NIHR Biomedical Research Centre in Gastrointestinal and Liver Diseases at Nottingham University Hospitals NHS Trust The University of Nottingham Nottingham UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Phillips","sequence":"additional","affiliation":[{"name":"NIHR Biomedical Research Centre in Gastrointestinal and Liver Diseases at Nottingham University Hospitals NHS Trust The University of Nottingham Nottingham UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Monaghan","sequence":"additional","affiliation":[{"name":"NIHR Biomedical Research Centre in Gastrointestinal and Liver Diseases at Nottingham University Hospitals NHS Trust The University of Nottingham Nottingham UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Fateen","sequence":"additional","affiliation":[{"name":"NIHR Biomedical Research Centre in Gastrointestinal and Liver Diseases at Nottingham University Hospitals NHS Trust The University of Nottingham Nottingham UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Samuel","sequence":"additional","affiliation":[{"name":"NIHR Biomedical Research Centre in Gastrointestinal and Liver Diseases at Nottingham University Hospitals NHS Trust The University of Nottingham Nottingham UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Ghosh","sequence":"additional","affiliation":[{"name":"NIHR Biomedical Research Centre Institute of Translational Medicine College of Medical and Dental Sciences University of Birmingham Birmingham UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. W.","family":"Moran","sequence":"additional","affiliation":[{"name":"NIHR Biomedical Research Centre in Gastrointestinal and Liver Diseases at Nottingham University Hospitals NHS Trust The University of Nottingham Nottingham UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,4,19]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2013.07.041"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2014.297"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2017.394"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2013.01.010"},{"key":"e_1_2_9_6_1","first-page":"CD000478","article-title":"Azathioprine and 6\u2010mercaptopurine for maintenance of remission in ulcerative colitis","volume":"18","author":"Timmer A","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199710093371502"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08512-4"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050516"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2005.11.030"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2006.11.041"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2011.10.032"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa067594"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13291"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215734"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2008.07.014"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2011.58"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2011.73"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/ctg.2015.63"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2011.04612.x"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011110"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.2010.06407.x"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2009.02.001"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i1.64"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12639"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00441-009-0834-6"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.gtc.2014.05.012"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215739"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043335"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2007.03.024"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60661-9"},{"key":"e_1_2_9_32_1","unstructured":"ClinicalTrials.gov.A study of the efficacy and safety of etrolizumab in ulcerative colitis participants who are refractory to or intolerant of tumor necrosis factor (TNF) inhibitors 2017.https:\/\/clinicaltrials.gov\/show\/NCT02100696. Accessed November 2017."},{"key":"e_1_2_9_33_1","unstructured":"ClinicalTrials.gov.A study to assess whether etrolizumab is a safe and effective treatment for participants with moderately to severely active Crohn's disease (CD).https:\/\/clinicaltrials.gov\/show\/NCT02394028. Accessed November 2017."},{"key":"e_1_2_9_34_1","unstructured":"SandbornWJ Pan\u00e9sJ JonesJ et\u00a0al.Etrolizumab as induction therapy in moderate to severe Crohn's disease: results from BERGAMOT Cohort 1. United European Gastroenterology Week; 2017; Barcelona Spain: United European Gastroenterology Journal; 2017."},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2013.03.014"},{"key":"e_1_2_9_36_1","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.4049\/jimmunol.159.3.1497","article-title":"Structure\u2010function analysis of the integrin beta 7 subunit: identification of domains involved in adhesion to MAdCAM\u20101","volume":"159","author":"Tidswell M","year":"1997","journal-title":"J Immunol"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.08.044"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051586"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2013.09.058"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2356"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI76369"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2013.05.002"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1513248"},{"key":"e_1_2_9_44_1","doi-asserted-by":"crossref","unstructured":"SandbornWJ FeaganBG D'HaensG et\u00a0al.OP096 Safety and efficacy of long\u2010term treatment with ozanimod an oral S1P receptor modulator in moderate to severe ulcerative colitis: TOUCHSTONE extension 2\u2010year follow up. United European Gastroenterology; October 2017; Barcelona Spain 2017. p. 40.","DOI":"10.14309\/00000434-201710001-00595"},{"key":"e_1_2_9_45_1","unstructured":"ClinicalTrials.gov.Efficacy and safety trial of RPC1063 for moderate to severe Crohn's disease.https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02531113. Accessed August 11 2017"},{"key":"e_1_2_9_46_1","unstructured":"FeaganBG SW SandbornWJ D'HaensG et\u00a0al.OP009 endoscopic and clinical efficacy demonstrated with oral ozanimod in moderately to severely active Crohn's disease. United European Gastroenterology; October 2017; Barcelona Spain 2017. p.5."},{"key":"e_1_2_9_47_1","unstructured":"ClinicalTrials.gov.A phase 3 multicenter open\u2010label extension trial of oral RPC1063 as therapy for moderate to severe ulcerative colitis.https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02531126. Accessed 11 August 2017."},{"key":"e_1_2_9_48_1","unstructured":"ClinicalTrials.gov.A phase 3 multicenter randomized double\u2010blind placebo\u2010controlled trial of oral RPC1063 as induction and maintenance therapy for moderate to severe ulcerative colitishttps:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02435992. Accessed 11 August 2017."},{"key":"e_1_2_9_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2017.03.007"},{"key":"e_1_2_9_50_1","unstructured":"ClinicalTrials.gov.Safety and efficacy of APD334 in patients with ulcerative colitis.https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02447302. Accessed 11 August 2017."},{"key":"e_1_2_9_51_1","unstructured":"ClinicalTrials.gov.Extension study of APD334\u2010003 in patients with moderately to severely active ulcerative colitis.https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02536404. Accessed 11 August 2017"},{"key":"e_1_2_9_52_1","unstructured":"ClinicalTrials.gov.A phase II open\u2010label multicentre study to evaluate the long\u2010term safety and efficacy of MT\u20101303 in subjects with moderate to severe active Crohn's disease who have completed the MT 1303\u2010E13 study. Available from:https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02389790. Accessed 11 August 2017."},{"key":"e_1_2_9_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2012.01.001"},{"key":"e_1_2_9_54_1","doi-asserted-by":"crossref","unstructured":"DaneseD NM KoponA ZakkoS et\u00a0al.OP006 Apremilast for active ulcerative colitis: a phase 2 randomised double\u2010blind placebo\u2010controlled induction study ECCO Vienna Austria: Journal of Crohn's Colitis; 2018. p. S004\u2013S5. ; 16 February 2018.","DOI":"10.1093\/ecco-jcc\/jjx180.004"},{"key":"e_1_2_9_55_1","unstructured":"ClinicalTrials.gov.Efficacy and safety study of apremilast to treat active ulcerative colitis (UC) 2018.https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02289417. Accessed 27 February 2018."},{"key":"e_1_2_9_56_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.168.10.5342"},{"key":"e_1_2_9_57_1","doi-asserted-by":"publisher","DOI":"10.1007\/PL00012423"},{"key":"e_1_2_9_58_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.MIB.0000172807.26748.16"},{"key":"e_1_2_9_59_1","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.20993"},{"key":"e_1_2_9_60_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra020831"},{"key":"e_1_2_9_61_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2014.104"},{"key":"e_1_2_9_62_1","unstructured":"ClinicalTrials.gov.A randomized double\u2010blind placebo\u2010controlled study of the efficacy and safety of a 12\u2010week add\u2010on treatment with LT\u201002 vs. placebo in subjects with ulcerative colitis refractory to standard treatment with mesalamine.https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02849951. Accessed 25 August 2017."},{"key":"e_1_2_9_63_1","unstructured":"ClinicalTrials.gov.Randomized double\u2010blind double\u2010dummy placebo\u2010controlled phase III clinical trial on the efficacy and safety of a 12\u2010weeks add\u2010on treatment with LT 02 vs. placebo in patients with ulcerative colitis refractory to standard treatment with mesalamine.https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02142725. Accessed 25 August 2017."},{"key":"e_1_2_9_64_1","unstructured":"ClinicalTrials.gov.Randomized double\u2010blind double\u2010dummy placebo\u2010controlled phase III clinical trial on the efficacy and safety of a 48\u2010weeks treatment with gastro\u2010resistant phosphatidylcholine (LT\u201002) versus placebo versus mesalamine for maintenance of remission in patients with ulcerative colitis.https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02280629. Accessed 25 August 2017."},{"key":"e_1_2_9_65_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2013.04.056"},{"key":"e_1_2_9_66_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12900"},{"key":"e_1_2_9_67_1","unstructured":"ClinicalTrials.gov.Exploratory phase II randomized double\u2010blind placebo\u2010controlled proof\u2010of\u2010concept study to evaluate the safety tolerability efficacy pharmacokinetics and pharmacodynamics of GLPG0974 in subjects with mild to moderate ulcerative colitis.https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01829321. Accessed 25 August 2017."},{"key":"e_1_2_9_68_1","unstructured":"ClinicalTrials.gov.A multicenter open\u2010label extension study to assess the safety and tolerability of LYC\u201030937\u2010EC in subjects with active ulcerative colitis.https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02764229."},{"key":"e_1_2_9_69_1","unstructured":"ClinicalTrials.gov.A randomized double\u2010blind placebo\u2010controlled parallel group study to assess the efficacy and safety of induction therapy with LYC\u201030937\u2010EC in subjects with active ulcerative colitis.https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02762500. Accessed 14 August 2017"},{"key":"e_1_2_9_70_1","unstructured":"ClinicalTrials.gov.A phase 2a randomised double\u2010blind placebo\u2010controlled study to evaluate the safety\/tolerability and efficacy of TOP1288 200\u00a0mg rectal solution once daily for 4 weeks in symptomatic ulcerative colitis patients with moderate to severe disease activity.https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02888379. Accessed 24 August 2017."},{"key":"e_1_2_9_71_1","unstructured":"ClinicalTrials.gov.A phase 1 study to evaluate the safety tolerability and pharmacokinetics of TOP1288 oral single ascending and multiple doses in healthy volunteers.https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03071081. Accessed 25 August 2017."},{"key":"e_1_2_9_72_1","unstructured":"ClinicalTrials.gov.A multicentre randomised double\u2010blind (sponsor unblinded) placebo\u2010controlled study with open label extension to investigate the safety and tolerability pharmacokinetics pharmacodynamics and efficacy of GSK2982772 in subjects with active ulcerative colitis.https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02903966. Accessed 25 August 2017."},{"key":"e_1_2_9_73_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2007.12.012"},{"key":"e_1_2_9_74_1","unstructured":"ClinicalTrials.gov.A randomized double\u2010blind 12\u2010week placebo\u2010controlled study followed by a 12\u2010week extension phase without placebo to evaluate the efficacy and safety of oral VB\u2010201 in subjects with mild to moderate ulcerative colitis.https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01839214. Accessed 12 August 2017."},{"key":"e_1_2_9_75_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjw036"},{"key":"e_1_2_9_76_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-014-0017-6"},{"key":"e_1_2_9_77_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1104318"},{"key":"e_1_2_9_78_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.26007"},{"key":"e_1_2_9_79_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2013.11.023"},{"key":"e_1_2_9_80_1","doi-asserted-by":"publisher","DOI":"10.1177\/1756285614529615"},{"key":"e_1_2_9_81_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.1000097"},{"key":"e_1_2_9_82_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2012.07.003"},{"key":"e_1_2_9_83_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2010.07.009"},{"key":"e_1_2_9_84_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awt023"},{"key":"e_1_2_9_85_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2014-307118"},{"key":"e_1_2_9_86_1","doi-asserted-by":"crossref","unstructured":"D'HaensGR SandbornW ColombelJW et\u00a0al.Su1084 pharmacokinetics of laquinimod in patients with active moderate to severe\u00a0Crohn's disease. DDW; May 2014. Gastroenterology 2014. p.S\u2010368.","DOI":"10.1016\/S0016-5085(14)61333-0"},{"key":"e_1_2_9_87_1","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1172\/JCI12821","article-title":"Blocking SMAD7 restores TGF\u2010beta1 signaling in chronic inflammatory bowel disease","volume":"108","author":"Monteleone G","year":"2001","journal-title":"J Clin Investig"},{"key":"e_1_2_9_88_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2016-312912"},{"key":"e_1_2_9_89_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-60761-869-0_21"},{"key":"e_1_2_9_90_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1407250"},{"key":"e_1_2_9_91_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13526"},{"key":"e_1_2_9_92_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2015.120"},{"key":"e_1_2_9_93_1","unstructured":"ClinicalTrials.gov.A phase 2 open\u2010label multicenter study to explore the efficacy and safety of MONGERSON (GED\u20100301) in subjects with active ulcerative colitis. Available from:https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02601300. Accessed 11 August 2017."},{"key":"e_1_2_9_94_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.gtc.2014.05.011"},{"key":"e_1_2_9_95_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2013.06.007"},{"key":"e_1_2_9_96_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-09-115030"},{"key":"e_1_2_9_97_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.00311.2015"},{"key":"e_1_2_9_98_1","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2015-0031"},{"key":"e_1_2_9_99_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.24567"},{"key":"e_1_2_9_100_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14018"},{"key":"e_1_2_9_101_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112168"},{"key":"e_1_2_9_102_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-015-0239-9"},{"key":"e_1_2_9_103_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.09.001"},{"key":"e_1_2_9_104_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606910"},{"key":"e_1_2_9_105_1","unstructured":"LichtensteinGR LoftusE BloomS et\u00a0al.OP095 tofacitinib an oral janus kinase inhibitor in the treatment of ulcerative colitis: open\u2010label long\u2010term extension study. United European Gastrroenterology; October 2017; Barcelona Spain 2017. pp.39\u201340."},{"key":"e_1_2_9_106_1","unstructured":"ClinicalTrials.gov.A phase 1a double\u2010blinded randomized placebo controlled single ascending dose (SAD) study to evaluate the safety tolerability and systemic exposure of TD\u20103504 in healthy subjects and subjects with ulcerative colitis (UC).https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03103412. Accessed 14 August 2017."},{"key":"e_1_2_9_107_1","unstructured":"ClinicalTrials.gov.This study is an open label long\u2010term extension study for subjects with moderate to severe ulcerative colitis designed to evaluate long term therapy of CP\u2010690 550.https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01470612. Accessed 20 August 2017."},{"key":"e_1_2_9_108_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2014.01.029"},{"key":"e_1_2_9_109_1","doi-asserted-by":"crossref","unstructured":"Pan\u00e9sJ SandbornW SchreiberS et\u00a0al.855 efficacy and safety of tofacitinib for oral induction therapy in patients with moderate to severe crohn's disease: results of a phase 2B randomized placebo\u2010controlled trial [Abstract]. DDW; April 2016: Gastroenterology; 2016. pp.S182\u2010S183.","DOI":"10.1016\/S0016-5085(16)30698-9"},{"key":"e_1_2_9_110_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2016-312735"},{"key":"e_1_2_9_111_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0904492"},{"key":"e_1_2_9_112_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)32537-5"},{"key":"e_1_2_9_113_1","unstructured":"VermeireSVDAA JamoulC TassetC HarrisonP D'HaensGR.OP005 Effect of disease duration and location on clinical remission in Crohn's disease patients treated with filgotinib a selective JAK1 inhibitor: post\u2010hoc analysis from the phase 2 Fitzroy study. United European Gastroenterology October 2017; Barcelona Spain 2017. p.2 3."},{"key":"e_1_2_9_114_1","unstructured":"ClinicalTrials.gov.A long\u2010term extension study to evaluate the safety of filgotinib in subjects with Crohn's disease.https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02914600. Accessed 14 August 2017."},{"key":"e_1_2_9_115_1","unstructured":"ClinicalTrials.gov.Combined phase 3 double\u2010blind randomized placebo\u2010controlled studies evaluating the efficacy and safety of filgotinib in the induction and maintenance of remission in subjects with moderately to severely active Crohn's disease.https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02914561. Accessed 14 August 2017."},{"key":"e_1_2_9_116_1","unstructured":"ClinicalTrials.gov.A long\u2010term extension study to evaluate the safety of filgotinib in subjects with ulcerative colitis.https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02914535. Accessed 14 August 2017."},{"key":"e_1_2_9_117_1","unstructured":"ClinicalTrials.gov.Combined phase 2b\/3 double\u2010blind randomized placebo\u2010controlled studies evaluating the efficacy and safety of filgotinib in the induction and maintenance of remission in subjects with moderately to severely active ulcerative colitis. Available from:https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02914522. Accessed 14 August 2017."},{"key":"e_1_2_9_118_1","doi-asserted-by":"crossref","unstructured":"SanbornWJ FeaganB PanesJ et\u00a0al.OP007 safety and efficacy of upadacitinib (ABT\u2010494) an oral JAK1 inhibitor as induction therapy in patients with Crohn's disease: results from CELEST. United European Gastroenterology Barcelona Spain2017. p. 3 4.","DOI":"10.1016\/S0016-5085(17)34357-3"},{"key":"e_1_2_9_119_1","unstructured":"A multicenter randomized double\u2010blind placebo\u2010controlled study of ABT\u2010494 for the induction of symptomatic and endoscopic remission in subjects with moderately to severely active Crohn's disease who have inadequately responded to or are intolerant to immunomodulators or anti\u2010TNF therapy2017.https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02365649. Accessed 11 August 2017."},{"key":"e_1_2_9_120_1","doi-asserted-by":"crossref","unstructured":"SchreiberSP\u2010BL BolandB HigginsPD et\u00a0al.OP022 rapidity of clinical and laboratory improvements following upadacitinib induction treatment: data from the CELEST study ECCO; 16 February 2018. Vienna Austria: Journal of Crohn's and Colitis; 2018. p.S015.","DOI":"10.1093\/ecco-jcc\/jjx180.021"},{"key":"e_1_2_9_121_1","unstructured":"A study to evaluate the safety and efficacy of ABT\u2010494 for induction and maintenance therapy in subjects with moderately to severely active ulcerative colitis 2017.https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02819635. Accessed 11 August 2017."},{"key":"e_1_2_9_122_1","unstructured":"ClinicalTrials.gov.A phase 2b multicenter randomized double\u2010blind placebo\u2010controlled parallel group dose\u2010response study evaluating the efficacy and safety of JNJ\u201054781532 in subjects with moderately to severely active ulcerative colitis.https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01959282. Accessed 14 August 2017."},{"key":"e_1_2_9_123_1","unstructured":"ClinicalTrials.gov.A phase 1b multi\u2010center randomized double\u2010blind multi\u2010dose placebo\u2010controlled study to evaluate the safety tolerability pharmacodynamics and plasma exposure of TD\u20101473 in subjects with moderately\u2010to\u2010severely active ulcerative colitis.https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02818686. Accessed 14 August 2017."},{"key":"e_1_2_9_124_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2005.07.053"},{"key":"e_1_2_9_125_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2012.09.016"},{"key":"e_1_2_9_126_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2011-301668"},{"key":"e_1_2_9_127_1","doi-asserted-by":"publisher","DOI":"10.1124\/pr.55.2.4"},{"key":"e_1_2_9_128_1","first-page":"374","article-title":"Targeting mucosal healing in Crohn's disease","volume":"7","author":"Kakkar A","year":"2011","journal-title":"Gastroenterol Hepatol"},{"key":"e_1_2_9_129_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2012.333"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fapt.14669","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/apt.14669","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,10]],"date-time":"2023-09-10T18:43:37Z","timestamp":1694371417000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/apt.14669"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,19]]},"references-count":128,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["10.1111\/apt.14669"],"URL":"https:\/\/doi.org\/10.1111\/apt.14669","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,19]]},"assertion":[{"value":"2017-11-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-03-25","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-04-19","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}